NeuroSense Therapeutics

Company Overview

Snapshot

Founded in February 2017 by Alon Ben-Noon, NeuroSense Therapeutics operates with 11–50 employees. The company has raised $24.2M across 7 funding rounds from 2 investors. In December 2021, NeuroSense Therapeutics completed its Initial Public Offering on the NASDAQ Capital Market.

Business overview

NeuroSense Therapeutics is a drug development company focused on creating treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its core product, PrimeC, is a unique formulation combining two FDA-approved compounds. The company is currently conducting clinical trials for PrimeC in ALS patients in both Israel and the United States, serving the pharmaceutical and life sciences industries within the Health Tech & Life Sciences sector.

Strategic signal

In November 2025, NeuroSense Therapeutics received FDA clearance to initiate a pivotal Phase 3 trial for PrimeC in ALS. This regulatory approval is a significant validation of the drug's potential and marks a critical step towards commercialization, signaling strong progress in addressing a high-unmet medical need within the neurodegenerative disease market.

Company Intelligence Q&A

What is NeuroSense Therapeutics' primary focus?

NeuroSense Therapeutics is a drug development company focused on creating treatments for patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

When did NeuroSense Therapeutics go public?

NeuroSense Therapeutics went public on NASDAQ in December 2021.

What is PrimeC?

PrimeC is NeuroSense Therapeutics' lead drug candidate, a unique formulation combining two FDA-approved compounds for unrelated conditions, developed for the treatment of ALS and Alzheimer's.

Has NeuroSense Therapeutics received any recent regulatory clearances for PrimeC?

In November 2025, NeuroSense Therapeutics received FDA clearance to initiate a pivotal Phase 3 trial for PrimeC in ALS.

What recent patent was granted to NeuroSense Therapeutics?

In September 2024, NeuroSense Therapeutics was granted a key U.S. patent for its novel PrimeC formulation, which is its lead asset for ALS and Alzheimer's.